Business
Novo Nordisk’s Wegovy pill launch draws new wave of patients to GLP-1s
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.”
Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest after the pandemic, at 270 pounds.
Zuckerman said GLP-1 injections were out of the question, because she’s afraid of needles. But when the first GLP-1 pill for obesity became available in early January, Zuckerman called her doctor immediately, she said.
Almost a month after starting Novo Nordisk‘s new Wegovy pill shortly after it launched, she said, she had lost around 11 pounds.
Zuckerman is among tens of thousands of patients who drove an explosive demand for prescriptions for Novo’s pill just three months into its launch. Many of them share a common thread: They had long held off on using GLP-1s due to barriers such as high out-of-pocket costs for injections or a fear of needles.
That’s one of the earliest takeaways from the rollout: Novo’s pill appears to be expanding the obesity treatment market, largely drawing in new patients rather than converting existing ones from injections. CNBC spoke with five U.S. patients who recently started the pill following its launch, all of whom said they have not previously taken branded GLP-1 injections.
But it’s early days for the pill. Many patients have yet to reach higher doses of the drug, and their experiences vary. It will take more time to determine how effective the pill is in supporting patients’ long-term weight loss journeys, whether it helps keep users on GLP-1s for longer than injections do and whether demand for Novo’s product will hold in the face of fresh competition from Eli Lilly.
Novo has a head start in the pill arena over Lilly, which just won U.S. approval of its own GLP-1 drug for obesity last week. Analysts previously told CNBC they still expect that rival pill, called Foundayo, to capture a segment of the market, in part because it lacks the dietary restrictions that come with Novo’s oral drug.
Still, the Wegovy pill appears to have had the most explosive launch of a GLP-1 product yet. The latest number that Novo disclosed in February is that more than 600,000 prescriptions had been written since its launch, including for more than 3,000 patients in the first week.
Analysts at BMO Capital Markets attributed some of the early uptake to an “attractive” entry price of $149 per month and its connection to the well-known Wegovy brand. The pill carries one of the lowest cash prices for a GLP-1 therapy, ranging from $149 to $299 per month, depending on the dose.
Even so, the pill’s launch has done little to boost Novo’s stock price, as the Danish drugmaker is struggling to win back market share from Lilly in the broader obesity space and convince investors that its drug pipeline can help it grow beyond its existing products.
Novo is expected to report first-quarter sales, which will include the pill for the first time, in May. But sales of the overall Wegovy portfolio are expected to increase from $13.5 billion in 2026 to $18.9 billion in 2031, with the pill contributing $2.76 billion, according to a March GlobalData report.
Reaching new patients
The Wegovy pill is attracting patients with a fear of needles, which is estimated to affect up to 25% of U.S. adults. But the drug is also an alternative for those who have had difficulty accessing branded GLP-1 injections or other medications.
“There are a handful of patients that don’t want to be stung by the needle in the case of a vial and syringe, or stung by the price,” Jamey Millar, Novo’s head of U.S. operations, told CNBC in an interview last week. “We’re appealing to both.”
Dr. Eduardo Grunvald, medical director of the UC San Diego Health Center for Advanced Weight Management, said the main reason he’s prescribed the Wegovy pill to some patients is cost, since its cash prices are slightly lower than those of injections. But Grunvald said overall, obesity medicine specialists like him will still be inclined to prescribe injections over oral drugs, in part because the shots are more effective.
A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026.
George Frey | Bloomberg | Getty Images
Cost was a deciding factor for Amy Sawyer-Williams, who works at a theater company in Raleigh, North Carolina, and has gestational diabetes. In 2023, a few years after her son was born, she said, she began developing prediabetes and met the criteria for obesity. She said she would have started using GLP-1 injections sooner, but her insurance would not cover them for her.
That was long before Novo and Lilly slashed the cash prices of their obesity and diabetes injections.
The list prices of their shots are roughly $1,000 per month before insurance and other rebates, or discounts for cash-paying patients — a sum that has long prevented many others from starting and staying on treatment. Novo has committed to cutting the monthly list prices of its drugs in the U.S. by up to 50%, but that change won’t go into effect until 2027.
High prices also shut Sawyer-Williams out from taking the branded weight management treatment Contrave, pushing her to combine two generic medications to mimic the drug’s effects, she said. But earlier this year, she said, her endocrinologist recommended the Wegovy pill, in part due to its lower $149 per month pricing for the starting dose.
Sawyer-Williams became the first patient at her doctor’s practice and local Walgreens to take the pill, starting in mid-January, she said.
Some Wegovy pill users are patients who wanted to switch over from injections, said Dr. Heather Hofflich, a physician and endocrinologist at UCSD Health. She said she’s prescribed the pill for some people whose insurance stopped covering the injections but who want to continue treatment.
Hofflich said she has also prescribed the oral drug to patients who lost weight initially on a shot but are now trying the pill to maintain that progress.
Early progress
While it’s still early, some patients said they’re already benefiting from taking Novo’s drug.
Zuckerman was initially skeptical of how effective the product would be, because it’s an oral medication. But, she said, “I swear I felt the impact on the first day,” particularly decreased appetite and disinterest in food.
“Things that used to give me enjoyment, or things I used to binge on, they just don’t taste as good anymore, and I just don’t see the point in eating them, honestly,” Zuckerman said, listing coffee, cheese, bread and fries, among other food and beverages.
She said she dealt with nausea — a common side effect of the GLP-1 class — but that became more manageable after the first two weeks on the pill.
Zuckerman also said what matters more than the weight loss or food urges is how she feels: “My clothes are looser, I have more energy, I genuinely feel better.”
Cherie Marcus, 72, a retired fabric designer and theater editor based in Brooklyn, said she’s also seen gradual progress — even on the lowest 1.5-milligram dose of the drug. She said that over the last 30 years, after her daughter was born, she’s gained weight and seen her hemoglobin A1c — a key measure of blood sugar levels — creep up.
Marcus said she started the pill on Jan. 24, and has lost about a pound a week while taking the lowest dose for seven weeks. Patients typically increase their dosage after a month, but Marcus said she’s still taking the lowest strength as of early April.
But her weight has “leveled off” over the past few weeks, she said, so she will likely move to a higher dose if she stops losing weight entirely. Marcus sees herself taking the pill long term, with a goal of losing around 30 pounds.
Novo’s Millar last week said some patients may start on lower doses and “be perfectly fine with that,” hitting their own personal goals for weight loss. But the company is monitoring how many patients increase to higher doses of the drug, particularly the 9-mg and 25-mg versions.
Courtney Kim, a stay-at-home mom based in Pittsburgh, is among the patients taking the Wegovy pill who have yet to experience notable side effects.
While she doesn’t qualify as obese, Kim said, the “weight would just not come off” after she had her three children. She started the pill around mid-February after struggling to lose weight with the use of other prescription medications and supplements, she said.
Kim started at a weight of roughly 158 pounds and has so far lost nearly 7 pounds on the pill, she said. She recently started the 4-mg dose of the drug.
“It’s actually working, and I’m shocked that the weight is actually like coming off and staying off,” Kim said. “So far I’ve had a positive experience.”
Some patients wait and see
The early experience with the pill hasn’t been smooth for everyone. UCSD’s Hofflich said she had one patient who could not tolerate the pill due to its gastrointestinal side effects, which is a common issue with the injections, as well.
Another patient had to switch to an injection because the pill’s dietary restrictions — which involve taking it with a small amount of water and waiting 30 minutes before eating or drinking — did not fit into their lifestyle, Hofflich said. Two patients who haven’t seen progress on higher doses of the pill are switching to injections, she said.
Hofflich said other patients who haven’t seen progress on lower doses are starting to take higher doses to see if that will make a difference.
That includes a patient based in New Hampshire named Amy, who said she began taking the Wegovy pill in early February. She asked CNBC not to use her last name, for privacy reasons.
Amy said she initially considered a branded GLP-1 treatment two years ago after her weight crept up to 190 pounds, but her doctor said her insurance wouldn’t cover it. Amy then turned to cheaper, unapproved compounded versions of GLP-1s for a year and lost 30 pounds before stopping in November.
She said the two lowest doses of the Wegovy pill — 1.5 mg and 4 mg — “did absolutely nothing for me” over two months.
Novo’s cash discounts allowed Amy to pay roughly $300 total for a month’s worth of each dose, but she said she feels “frustrated” that she still feels hungry and has noticed no changes apart from side effects including constipation. Amy said her weight is “hovering” around 170 pounds.
“It just kind of felt like a waste of time,” she said.
Amy said she plans to start the 9-mg dose of the pill soon, hoping that she’ll begin to see the benefits of treatment. She said if that doesn’t work, she’ll discuss with her doctor whether to try the highest dose, 25 mg, or potentially turn back to compounded GLP-1s.
Meanwhile, Sawyer-Williams is restarting the lowest dose of the pill after pausing the drug due to gastrointestinal side effects. She said she was nervous about starting the pill, because she’s always had a sensitive stomach.
During her first three weeks on the 1.5-mg dose of the oral drug, she did not notice any weight loss, but experienced nausea if she didn’t eat, Sawyer-Williams said. She started to feel less interested in food by her fourth week, she said, but began taking the next dose, 4 mg, shortly after.
On the seventh day of taking that dose, Sawyer-Williams said, she experienced “the worst” nausea, vomiting and dehydration, which caused her to stop treatment.
“I wish I had just stayed on the 1.5” dose, she said. “I was really, really sick. Even when I quit the pill, I just couldn’t keep down water.”
Sawyer-Williams started at a weight of 177 pounds and lost five pounds overall after taking the drug, she said. She’s been off treatment for a few weeks, but started the lowest dose of the pill as of early April with new habits, including staying hydrated and starting to lift weights, she said.
“We’re going to just have to hope that it’s enough to help me,” she said, referring to the lowest dose.
Dr. Andrea Traina, Novo’s obesity medical director, recommended that patients who are struggling with side effects talk to their health-care provider about strategies to mitigate them. For example, she said some people may benefit from staying on a lower dose until they tolerate the drug better before increasing to a higher dosage.
“Treating obesity, just like most chronic diseases, is kind of a marathon, not a sprint,” Traina said in an interview. “So adding an extra month or two to help with tolerability upfront can help with kind of long-term success.”
Unanswered questions
Several questions remain about the long-term use of the pill, especially on higher doses, and it may not be the best obesity treatment for every patient, experts said.
Traina said each patient has an individual response, and they may respond well above or well below average in terms of weight loss and side effects. That can be tied to their genetics, environment or dietary habits, and experiences can vary slightly across certain populations and age groups, she said.
“It’s very tough to know why one patient’s responding to something and another isn’t,” Traina said, adding that it’s “one of the many benefits of having multiple treatment options available.”
Having an oral option at lower cash prices that “can be attainable for a larger population is a very good thing, to help us cure or alleviate this chronic disease state,” said UCSD’s Hofflich.
She said in the coming months, particularly with the rollout of Lilly’s new drug, “we’ll have many more stories and outcomes” of pills to evaluate, allowing for clearer comparisons between the two pills as well as injections.
Patients such as Zuckerman may offer an early glimpse of those who stand to benefit most from the pill — and the cases where it resonates.
“I was in this boat of seeing the pill as cheating and feeling like I had to lose the weight the hard way,” she said. “But that doesn’t work for everybody, and eventually I got to the point where I was like, do I want to be stubborn and try to do this the ‘right way,’ or do I want to die from being obese?”
“Jumping on the opportunity to the pill at this stage in my life was the right decision,” Zuckerman said.
Almost half of Australia’s mid-market business leaders are forecasting no real growth for the remainder of the year but claim cutting red tape in the federal budget could turn their prospects around, KPMG finds.
FOX Business’ Gerri Willis joins ‘Varney & Co.’ to report on the growing red vs. blue state divide over taxes, as new wealth levies target billionaires, property tax revolts spread nationwide and a wave of income tax cuts reshapes the economy
After months of campaigning for a first-of-its-kind retroactive wealth tax in California, the union-led effort is now taking its next step.
The Service Employees International Union–United Healthcare Workers West (SEIU-UHW) said it has collected more than 1.55 million signatures, according to a press release, nearly double the 875,000-signature requirement — to put a one-time tax on billionaire assets on the California ballot.
The California Billionaire Tax Act would target the net worth of roughly 200 residents and would impose a one-time 5% tax on the net worth of California residents with assets exceeding $1 billion. The tax would be due in 2027, and taxpayers could spread payments over five years, with interest, according to the Legislative Analyst’s Office.
If the measure is approved by voters in November, anyone who was a California resident on Jan. 1, 2026, would owe the tax, according to the proposal. In practical terms, a resident with $20 billion in net worth on that date would owe a one-time tax of $1 billion, payable over five years.
THE $1,600 LETTUCE: CALIFORNIA GROWERS WARN OF ‘MASTER PLAN’ STRANGLING FAMILY FARMS
Supporters argue the tax is a direct response to “cuts to Medicaid and other federal health insurance programs by the Trump administration last year.”
Attendees cheer during the speech of Sen. Bernie Sanders, I-Vt., during the campaign kickoff for the California Billionaire Tax Act in Los Angeles, Feb. 18, 2026. (Getty Images)
“Most Californians and most billionaires recognize how reasonable and necessary this proposal is — both to keep emergency rooms open and to save California businesses from closing,” SEIU-UHW chief of staff Suzanne Jimenez said in a press release.
“A very small group of the most controversial billionaires on the planet tried to stop Californians from being able to save their local emergency rooms and hospitals — but our current signature tally proves frontline healthcare workers will prevail in bringing this commonsense proposal to voters,” she continued. “When our growing coalition files these signatures, David will have won the first round against Goliath, but healthcare workers and our allies won’t quit until we fully protect our patients from the looming healthcare disaster that will be caused by $100 billion in cuts to California healthcare.”
‘The Big Money Show’ panel discusses California’s proposed wealth tax, the potential economic impact and the exodus from blue states.
The SEIU-UHW did not immediately respond to Fox News Digital’s request for comment.
Opponents of the measure have warned the tax could kill an estimated 108,000 high-paying jobs over the next 20 years, The New York Times reported Sunday. Democratic Gov. Gavin Newsom even acknowledged that the state’s proposed wealth tax is bad economics, previously saying he feels vindicated in opposing the proposal after reports showed some of California’s wealthiest residents moving money and businesses out of the state, warning the measure would damage the economy and drive away investment.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
California gubernatorial candidate Steve Hilton discusses new developments in the investigation into former California congressman Eric Swalwell on ‘The Evening Edit.’
While the Legislative Analyst’s Office predicts a temporary surge in cash, it warned of an “ongoing decrease in state income tax revenues of hundreds of millions of dollars or more annually” as billionaires flee the state in response.
Some of those public figures who moved their residencies or businesses out of California before the Jan. 1 retroactive tax deadline include Google co-founders Larry Page and Sergey Brin, Meta’s Mark Zuckerberg, Peter Thiel, Steven Spielberg, Uber’s Travis Kalanick and car loan magnate Don Hankey.
The bank’s operating profit stood at Rs 522 crore, 29% higher than last time’s Rs 404 crore on 16% higher total income at Rs 1792 crore against Rs 1542 crore.
Its net interest margin for the quarter rose to 4.18% from 3.91% seen in the year-ago quarter.
The net profit for FY26 stood at Rs 1338 crore as compared with Rs 1183 crore in FY25. The bank board proposed a final dividend of Rs 12.50 per equity share of the face value Rs 10 each, which is 125% dividend for FY26.
Managing director Salee S Nair said that the bank’s business growth in both the assets and liability sides has been the highest in the past 10 years
Its advances grew 20.3% year-on-year to Rs 53,379 crore white deposits rose 14.9% to Rs 61,712 crore. The lender’s asset quality improved with gross non-performing assets ratio declining to 0.73% at the end of March from 1.25% a year prior.
Kayne Anderson president Baker buys $339,250 in KYN stock
The announcement follows Trent’s earlier disclosure of the bonus issue alongside its Q4 results and a Rs 6 dividend. The company had at the time indicated that the record date would be announced separately.
The bonus issue marks a milestone for the Westside and Zudio parent, which has never issued bonus shares before. As part of the plan, Trent will issue around 17.77 crore equity shares of Re 1 face value each, capitalising a portion of its share premium reserves.
The company expects to complete the allotment of these bonus shares by June 21, drawing from its share premium pool, which stood at over Rs 1,900 crore as of March-end FY26.
A bonus issue involves distributing additional shares to existing shareholders at no extra cost, typically reflecting a company’s confidence in its financial position and growth outlook. While the move increases the total number of outstanding shares, it does not alter the company’s overall market capitalisation. However, it tends to improve stock liquidity and makes shares more accessible to retail investors.
Only those shareholders holding Trent shares as of May 29 will be eligible to receive the bonus allotment.
Trent reported a 26% growth in its consolidated net profit for the quarter ended March 31, 2026, at Rs 400 crore versus Rs 318 crore in the year-ago period. Its revenue from operations, meanwhile, rose 19% YoY to Rs 5,028 crore in Q4 FY26.Further, Trent has also earlier approved the plan to raise additional funds through the issue of equity shares via rights issue or other methods. The company announced an Employee Stock Option Plan (ESOP) to issue nearly 8.89 lakh shares to its eligible shareholders.
Pharma thinks it’s found the next frontier in preventing heart attacks.
Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a) can protect people from heart attacks.
If they can, the opportunity could be massive: an estimated one in five people worldwide have elevated Lp(a), and there’s not much they can do to lower it. Evidence from human genetics suggests the idea could work, but drugmakers don’t know for sure. That makes the first late-stage trial results from Novartis, expected later this year, important for the entire pipeline.
“History has taught us you can’t make assumptions,” said Dr. Steve Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic who is the principal investigator of Novartis’ Phase 3 Horizon trial of pelacarsen, the company’s experimental drug to lower Lp(a). “We thought raising HDL would be beneficial and that didn’t work, so I think we have to keep an open mind.”
Lp(a), or lipoprotein(a), was first discovered in 1963. It’s a more dangerous cousin to the well-known LDL cholesterol because it simultaneously clogs arteries and promotes blood clots, posing two risks with just one particle. Almost 50 years after Lp(a) was discovered, researchers found that people who have high levels of it had a more than twofold higher risk of heart attack than those who don’t.
How much Lp(a) a person has circulating in their body is almost entirely determined by their genes. Lifestyle factors like diet and exercise don’t influence Lp(a) levels like they do LDL levels, leaving people with few good options to reduce it.
Currently, doctors encourage people to focus on the factors they can change, such as lowering their LDL cholesterol, decreasing blood pressure, treating obesity and diabetes and exercising. Those strategies can help protect people from high Lp(a) for some time, Nissen said. New medicines could treat people for a longer time.
Novartis, Amgen and Lilly have already proven their experimental drugs slash levels of Lp(a) by more than 80%. Now, they will need to show that translates into tangible benefits. If that happens, the drugs could reach annual sales of $5.6 billion by 2032, according to consensus estimates from Evaluate, a pharmaceutical commercial intelligence firm.
“We don’t know how much you have to lower levels,” Nissen said. “We don’t know how high you have to be to benefit from getting your level lowered. Estimates of how much you have to lower levels to prevent events based upon genetic studies are highly variable, so we don’t have an answer, and we won’t have an answer until on the date that we unblind the trial.”
That should happen around the middle of the year, Novartis CEO Vas Narasimhan said on the company’s fourth-quarter earnings call in February. The trial is studying whether Novartis and its partner Ionis’ drug pelacarsen prevents outcomes like heart attacks and strokes in people with elevated levels of Lp(a) who already have cardiovascular disease. Novartis delayed the readout by a year because people weren’t experiencing events as quickly as the company expected in the yearslong trial.
Narasimhan has said that might have to do with the fact that researchers were managing participants’ other risk factors. He said Novartis is still excited to see the data and to potentially create “an entire new class of medicines that can help a whole group of patients that have no other option.”
Novartis’ drug uses a different mechanism than its next closest competitors from Amgen and Lilly. Those drugs, Amgen’s olpasiran and Lilly’s lepodisiran, looked more potent in mid-stage trials, leading to larger Lp(a) reductions.
Amgen’s pivotal trial results were expected later this year or early next before the company also pushed back the timeline. The company now says it plans to provide an update on timing in early 2027.
Jay Bradner, Amgen’s executive vice president of research and development, said it’s impossible to say why it’s taking longer for enough people to have heart attacks to analyze the results without seeing the data.
“The clarity of the signal from population genetics and the encouraging signs from [earlier trials] render this a very smart bet,” said Bradner. The forthcoming results from Novartis will provide direction on how Lp(a)-targeting drugs can affect clinical outcomes, he said, adding that he’s “very bullish about the hypothesis.”
Lilly expects to share data from its Phase 3 trial of lepodisiran in 2029. All of the trials are designed slightly differently, which could create variation in the results, said Dr. Michelle O’Donoghue, a cardiologist at the Mass General Brigham Heart & Vascular Institute and the principal investigator of Amgen’s Ocean(a) trial of olpasiran.
“So there’s reason to think that the magnitude of the benefit might be different across the different programs,” she said.
Despite the focus from drugmakers, few doctors test their patients’ Lp(a) levels. Less than 1% of adults were tested for it in the U.S. in 2024, and testing was concentrated in a handful of states, according to one study of electronic health records.
Screening involves a routine blood draw like what’s used to measure other types of cholesterol. Leading cardiology organizations recently started recommending every adult be tested for Lp(a) at least once in their life. Currently, some doctors are reluctant to screen people for a problem when they don’t have any medicines to offer them to treat it, Nissen and O’Donoghue said.
The Family Heart Foundation plans to advocate for adding Lp(a) to the standard lipid test that measures other types of cholesterol like LDL, said the organization’s CEO, Katherine Wilemon. Living with elevated Lp(a) and another genetic heart condition herself, Wilemon has pushed for more screening since experiencing a heart attack at 38 and founding the organization in 2011.
She said the Lp(a) drugs have already helped raise awareness about testing. If the treatments succeed in clinical trials, more screening could follow. Morningstar analyst Jay Lee thinks it could take time to build the market, especially since Novartis’ pelacarsen would initially be used for people with high Lp(a) levels and a history of cardiovascular events.
Amgen and Lilly are already testing whether drugs could protect people with elevated Lp(a) from having that first event. Those results are still years away, with Lilly’s trial expected to read out in 2029.
In the meantime, Lilly isn’t waiting to make more bets. The company is testing a daily pill, and it acquired a company that wants to use gene editing to slash Lp(a) levels with a one-time treatment.
“We’ve got a bunch of shots on goal,” Cleveland Clinic’s Nissen said. “We hope at least one of them ends up in the back of the net.”
Investors are skeptical, said Goldman Sachs analyst Asad Haider. They’re nervous what the delay in Novartis’ trial means for the drugs, and they’re concerned that even if the drugs work, it could take years for them to become mega-blockbusters, he said.
“That’s why this Novartis trial is going to be so important in how people think about the unlock,” Haider said.
Wilemon from the Family Heart Foundation thinks the market for the drugs is there. She sees screening as the most important issue and access as the second one. She points to PCSK9 inhibitors, powerful drugs that slash levels of LDL cholesterol, which struggled for years to gain traction until drugmakers lowered their prices.
But before uptake comes the data — and she said she and the whole Lp(a) community are crossing their fingers Novartis’ drug works.
Colombian peso drops 2.36% as leftist leads presidential polls
Coltin Stidham wanted to be a pilot, but his eyesight didn’t make the grade. Now, the high-school junior is training for another six-figure aviation job even more in demand.
Inside an 8,500-square-foot hangar at Middletown Regional Airport in southern Ohio, the 17-year-old is learning to become an aircraft maintenance technician—a job that doesn’t require a college degree, is AI-proof and, within several years, can earn more than $100,000.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
The threat that artificial intelligence tools will fuel a software apocalypse has rattled stocks, triggered record withdrawals from private-debt funds and stirred fears of a new type of credit crisis.
But a key market is sending a more mixed message: Not all software companies are equally endangered. While prices of software-company loans have fallen sharply on average since late January, a Wall Street Journal analysis of more than 100 loans showed wide variations in price moves, with parts of the sector hit much harder than others.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
The company’s vinegar-based coleslaw is formulated with probiotics.
Andy Cohen Reveals Who Helped Crack ‘Summer House’ Leak
LOVE FOR MONEY || CHAPTER 1 – KWADWO NKANSAH LIL WIN – WEEZY EMPIRE TV
Preston Davey trial told couple subjected tot to sleep deprivation and sexual assaults before death, court hears
Manchester United reach agreement with Casemiro over contract clause amid transfer speculation
US brings back mandatory military draft registration
Steven Gerrard disagrees with Gary Neville over ‘shock’ Chelsea and Arsenal claim | Football
-
Politics7 days agoGary Stevenson delivers timely reminder to register to vote as deadline TODAY
-
Fashion3 days agoWeekend Open Thread – Corporette.com
-
Crypto World2 days agoHyperliquid $HYPE Rally Builds Momentum as AI Sector Enters Prove-It Phase
-
Politics5 days agoMaking troops accountable for war crimes threatens US alliance, ex-SAS colonel warns
-
Politics5 days agoDisabled people challenge government SEND proposals over segregation concerns
-
Tech2 hours agoRegister Renaming | Hackaday
-
Business5 days agoRolls-Royce Voted UK’s Most Iconic Trade Mark as IPO Register Hits 150
-
Business4 days agoPatterson-UTI Energy, Inc. (PTEN) Q1 2026 Earnings Call Transcript
-
Politics5 days agoZack Polanski responds to home secretary’s taser threat
-
Sports1 day agoIPL 2026: Ruturaj Gaikwad registers slowest fifty of the season, enters all-time unwanted list | Cricket News
-
Crypto World6 days agoFive Value Stocks with Recovery Potential in 2026: PayPal (PYPL), Nike (NKE), and More
-
Politics5 days agoStarmer handler McSweeney to be dragged from shadows by Foreign Affairs Committee
-
Politics5 days ago
Wings Over Scotland | How To Get Away With Crimes
-
Crypto World6 days agoNew York sues Coinbase, Gemini over prediction market offerings
-
Entertainment6 days ago
Sydney Sweeney cameo cut from “The Devil Wears Prada 2”, source explains why (exclusive)
-
Business6 days agoHCL Tech share price tank over 9% after weak Q4. JPMorgan, HSBC & 3 others cut target price
-
Politics5 days ago‘Iran is still a nuclear threat’
-
Sports5 days agoTim Bradley names the current best in the world: “Better than Inoue and Usyk”
-
Crypto World6 days agoCrypto’s great hope in Senate’s Clarity Act still has a path to survive tight calendar
-
NewsBeat1 day agoLK Bennett closes all stores after entering administration
You must be logged in to post a comment Login